NDAORALTABLET
Approved
May 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
ZITHROMAX (azithromycin dihydrate) by Pfizer is drug. Approved for infection. First approved in 2002.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZITHROMAX (azithromycin dihydrate) is an oral tablet antibiotic approved in 2002 used to treat bacterial infections. It is a macrolide antibiotic that works by inhibiting bacterial protein synthesis. The drug is administered orally and has broad-spectrum activity against common respiratory and other bacterial pathogens.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30% intensity); brand teams will focus on transition strategies and generic defense initiatives.
Mechanism of Action
drug. [see ]
Indications (1)
Clinical Trials (4)
PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients
Started Dec 2013
8 enrolled
PharyngitisTonsillitis
Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)
Started Oct 2009
502 enrolled
Bacterial Infections
Zithromax EV in Community-Acquired Pneumonia (CAP)
Started Nov 2003
151 enrolled
Pneumonia
A Pediatric Taste Test Study of Omnicef Versus Zithromax Antibiotic Suspension Medications
Started Jan 2003
157 enrolled
Healthy
Worked on ZITHROMAX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.